癌症研究
肌动蛋白解聚因子
淋巴瘤
细胞生物学
生物
免疫学
细胞
肌动蛋白细胞骨架
遗传学
细胞骨架
作者
Ditipriya Mukherjee,Soumitra Marathe,Diksha Attrish,Vinanti Sawant,Bhavuk Dhamija,Sushant Kumar,Siddhi Wad,Moumita Basu,Neha Sharma,Hasmukh Jain,Steven R. Barthel,Rahul Purwar
标识
DOI:10.1158/1541-7786.c.8016655
摘要
<div>Abstract<p>Cutaneous T-cell lymphoma (CTCL) is a multistage disease characterized by rapid dissemination of malignant T lymphocytes from skin lesions to visceral organs and bone marrow. The cytokine IL-9 and its receptor (IL-9R) are aberrantly overexpressed in CTCL lesions and function to enhance tumor cell survival. In this study, we uncovered a critical new role for IL-9 as a potent inducer of migration of malignant T cells. Stimulation of IL-9R–expressing T-cell lymphoma cells with IL-9 induced a pseudohypoxic cellular state by elevating downstream levels of the promigratory and oxygen-sensing transcription factor hypoxia-inducible factor (HIF)-1α. High-throughput quantitative proteomic analyses of pseudohypoxic malignant T cells identified the actin-modulating protein cofilin-1 (CFL-1) as a promigratory CTCL-intrinsic target downstream of IL-9–HIF-1α signaling. Consistently, multicolor immunofluorescence staining revealed marked coexpression of CFL-1 with HIF-1α in both IL-9–treated human lymphoma cell lines and in patient CTCL skin biopsies compared with normal controls. Genetic knockdown of <i>IL9R</i> or <i>HIF1A</i> in human T-cell lymphoma lines by RNAi significantly reduced both HIF-1α and CFL-1 coexpression and reversed IL-9–induced migration. Finally, pharmacologic antagonism of HIF-1α activity using the FDA-designated orphan drug echinomycin significantly abrogated IL-9–triggered migration of both malignant T-cell lines and patient-derived T-cell lymphoma cells from CTCL biospecimens.</p>Implications:<p>Our results uncover a CTCL-intrinsic IL-9–HIF-1α–CFL-1 axis as a critical promoter of malignant T-cell migration. They further identify HIF-1α and CFL-1 as promising therapeutic targets to mitigate IL-9–induced CTCL dissemination.</p></div>
科研通智能强力驱动
Strongly Powered by AbleSci AI